Amgen buys cancer drugmaker for $10.4B

08/26/2013 | Reuters

Amgen agreed to acquire Onyx Pharmaceuticals for $125 per share, or around $10.4 billion, in the fifth-largest biotechnology deal ever. The agreement will give Amgen rights to several cancer drugs, including the multiple myeloma drug Kyprolis, liver and kidney cancer treatment Nexavar, and colon cancer drug Stivarga. The acquisition is expected to be finalized this year.

View Full Article in:

Reuters

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL